Influence of CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Expression on the Survival of Patients with Non-Metastatic Nasopharyngeal Carcinoma

References

• Chen YP, Chan A, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-031178151
   PubMed Web of Science ®Google Scholar
• Wang S, Li S, Shen L. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: a meta-analysis of the published literature. Curr Probl Cancer. 2018;42(3):302–318. doi:10.1016/j.currproblcancer.2018.03.00429759802
   PubMed Web of Science ®Google Scholar
• Bhattacharyya T, Babu G, Kainickal CT. Current role of chemotherapy in nonmetastatic nasopharyngeal cancer. J Oncol. 2018;2018:3725837. doi:10.1155/2018/372583730364069
   PubMed Web of Science ®Google Scholar
• Jiang Y, Qu S, Pan X, Huang S, Zhu X. Prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma. Sci Rep. 2020;10(1):861. doi:10.1038/s41598-020-57968-x31965045
   PubMed Web of Science ®Google Scholar
• Suzuki C, Blomqvist L, Sundin A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23(4):948–954. doi:10.1093/annonc/mdr35021832285
   PubMed Web of Science ®Google Scholar
• Zhao Y, Shen L, Huang X, et al. Prognostic analysis of patients with locally advanced nasopharyngeal carcinoma following intensity modulated radiation therapy. Oncol Lett. 2018;15(4):4445–4450. doi:10.3892/ol.2018.785029552107
   PubMed Web of Science ®Google Scholar
• Locke JM, Wei FY, Tomizawa K, Weedon MN, Harries LW. A cautionary tale: the non-causal association between type 2 diabetes risk SNP, rs7756992, and levels of non-coding RNA, CDKAL1-v1. Diabetologia. 2015;58(4):745–748. doi:10.1007/s00125-015-3508-925634229
   PubMed Web of Science ®Google Scholar
• Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet. 2007;39(6):770–775. doi:10.1038/ng204317460697
   PubMed Web of Science ®Google Scholar
• Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316(5829):1331–1336. doi:10.1126/science.114235817463246
   PubMed Web of Science ®Google Scholar
• Chen MM, O’Mara TA, Thompson DJ, et al. GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. Hum Mol Genet. 2016;25(12):2612–2620.27008869
   PubMed Web of Science ®Google Scholar
• Parada HJ, Cleveland RJ, North KE, et al. Genetic polymorphisms of diabetes-related genes, their interaction with diabetes status, and breast cancer incidence and mortality: the Long Island Breast Cancer Study Project. Mol Carcinog. 2019;58(3):436–446.30457165
   PubMed Web of Science ®Google Scholar
• Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group Phase II trial 0225. J Clin Oncol. 2009;27(22):3684–3690. doi:10.1200/JCO.2008.19.910919564532
   PubMed Web of Science ®Google Scholar
• Liu SC, Tsang NM, Chiang WC, et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J Clin Invest. 2013;123(12):5269–5283. doi:10.1172/JCI6342824270418
   PubMed Web of Science ®Google Scholar
• Xiao G, Cao Y, Qiu X, Wang W, Wang Y. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. Bmc Cancer. 2013;13:226. doi:10.1186/1471-2407-13-22623642234
   PubMed Web of Science ®Google Scholar
• Lu X, Wang FL, Guo X, et al. Favorable prognosis of female patients with nasopharyngeal carcinoma. Chin J Cancer. 2013;32(5):283–288. doi:10.5732/cjc.012.1005822980419
   PubMedGoogle Scholar
• Dou H, Hu D, Lam C, Liu Y, Wang X, Zhang W. Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Macao. Chin J Cancer Res. 2014;26(2):148–158. doi:10.3978/j.issn.1000-9604.2014.03.0124826055
   PubMed Web of Science ®Google Scholar
• You R, Hua YJ, Liu YP, et al. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics. 2017;7(8):2314–2324. doi:10.7150/thno.1971028740554
   PubMed Web of Science ®Google Scholar
• Lee AW, Law SC, Foo W, Poon YF, Chan DK. Nasopharyngeal carcinoma: local control by megavoltage irradiation. Br J Radiol. 1993;66(786):528–536. doi:10.1259/0007-1285-66-786-5288330138
   PubMed Web of Science ®Google Scholar
• Sun XS, Liu SL, Luo MJ, et al. The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a Cohort Study From 1990 to 2012. Int J Radiat Oncol Biol Phys. 2019;105(3):581–590. doi:10.1016/j.ijrobp.2019.06.254931319091
   PubMed Web of Science ®Google Scholar
• Bellmunt J. Stem-like signature predicting disease progression in early stage bladder cancer. The Role of E2F3 and SOX4. Biomedicines. 2018;6(3):85. doi:10.3390/biomedicines6030085
   PubMed Web of Science ®Google Scholar
• Sainz J, Rudolph A, Hoffmeister M, et al. Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. J Clin Endocrinol Metab. 2012;97(5):E845–E851. doi:10.1210/jc.2011-256522419714
   PubMed Web of Science ®Google Scholar
• Liang Q, Li L, Zhang J, et al. CDK5 is essential for TGF-beta1-induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep. 2013;3:2932. doi:10.1038/srep0293224121667
   PubMed Web of Science ®Google Scholar
• Jia Y, Duan Y, Liu T, et al. LncRNA TTN-AS1 promotes migration, invasion, and epithelial mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5. Cell Death Dis. 2019;10(8):573. doi:10.1038/s41419-019-1811-y31363080
   PubMed Web of Science ®Google Scholar
• Sun SS, Zhou X, Huang YY, et al. Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma. Mol Cancer. 2015;14:213. doi:10.1186/s12943-015-0487-x26690371
   PubMed Web of Science ®Google Scholar
• Peng H, Zhang J, Zhang PP, et al. ARNTL hypermethylation promotes tumorigenesis and inhibits cisplatin sensitivity by activating CDK5 transcription in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2019;38(1):11. doi:10.1186/s13046-018-0997-730621723
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhong T, Dang Y, Li Z, Li P, Chen G. Aberrant expression of CDK5 infers poor outcomes for nasopharyngeal carcinoma patients. Int J Clin Exp Pathol. 2015;8(7):8066–8074.26339373
   PubMed Web of Science ®Google Scholar
• Li HM, Li P, Qian YJ, et al. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma. Bmc Cancer. 2016;16(1):946. doi:10.1186/s12885-016-2974-x27955638
   PubMed Web of Science ®Google Scholar
• Li Y, Chen QY, Tang LQ, et al. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study. Bmc Cancer. 2017;17(1):567. doi:10.1186/s12885-017-3552-628836950
   PubMed Web of Science ®Google Scholar
• Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23. doi:10.1016/j.ejca.2016.12.03928214653
   PubMed Web of Science ®Google Scholar
• Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–1520. doi:10.1016/S1470-2045(16)30410-727686945
   PubMed Web of Science ®Google Scholar